

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

Drug	NICE-approved use	NICE TA link
Abiraterone	Prostate cancer (castration-resistant) following cytotoxic chemotherapy - Last updated: 27 July 2016	http://guidance.nice.org.uk/TA259
Abiraterone	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults - Last updated: 27 July 2016	https://www.nice.org.uk/guidance/ta387
Adalimumab	Moderate to severe hidradenitis suppurativa (this may only be initiated by Specialist Dermatology Centres).	https://www.nice.org.uk/guidance/ta392
Adalimumab	Plaque psoriasis in children and young people	https://www.nice.org.uk/guidance/ta455
Adalimumab	Non-infectious uveitis (this may only be initiated by Specialist Ophthalmology Centres).	https://www.nice.org.uk/guidance/ta460
Adefovir	Hepatitis B (chronic)	http://guidance.nice.org.uk/TA96
Afatinib	Lung cancer (non small cell, EGFR mutation positive)	http://guidance.nice.org.uk/TA310
Alfa interferon	Hepatitis C	http://guidance.nice.org.uk/TA75
Alirocumab	Primary hypercholesterolaemia or mixed dyslipidaemia	https://www.nice.org.uk/guidance/ta393
Arsenic trioxide	Acute promyelocytic leukaemia	https://www.nice.org.uk/guidance/ta526
Asfotase alfa	Paediatric-onset hypophosphatasia	https://www.nice.org.uk/guidance/hst6
Ataluren	Duchenne Muscular Dystrophy	https://www.nice.org.uk/guidance/hst3
Atezolizumab	Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	https://www.nice.org.uk/guidance/ta492
Atezolizumab	Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	https://www.nice.org.uk/guidance/ta525
Autologous chondrocyte implantation	Symptomatic articular cartilage defects of the knee	https://www.nice.org.uk/guidance/ta477
Avelumab	Metastatic Merkel cell carcinoma	https://www.nice.org.uk/guidance/ta517
Axicabtagene ciloleucel	Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	https://www.nice.org.uk/guidance/ta559
Axitinib	Advanced renal cell carcinoma after failure of prior systemic treatment	https://www.nice.org.uk/guidance/ta333
Basiliximab	Renal transplantation – immunosuppressive regimens (adults)	http://guidance.nice.org.uk/TA85
Basiliximab	Renal transplantation – immunosuppressive regimens for children and adolescents	http://guidance.nice.org.uk/TA99
Belimumab	Active autoantibody-positive systemic lupus erythematosus in adults – prescribing is limited to approved specialist centres only.	https://www.nice.org.uk/guidance/ta397
Benralizumab	Severe eosinophilic asthma	https://www.nice.org.uk/guidance/ta565
Blinatumomab	Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Note (Aug-17): this therapy may be considered in future.	https://www.nice.org.uk/guidance/ta450

Boceprevir	Hepatitis C (genotype 1)	http://guidance.nice.org.uk/TA253
Burosumab	X-linked hypophosphataemia in children and young people	https://www.nice.org.uk/guidance/hst8
Cabazitaxel	Hormone-relapsed metastatic prostate cancer treated with docetaxel	https://www.nice.org.uk/guidance/ta391
Cabozantinib	Previously treated advanced renal cell carcinoma	https://www.nice.org.uk/guidance/ta463
Cabozantinib	Medullary thyroid cancer	https://www.nice.org.uk/guidance/ta516
Cabozantinib	Untreated advanced renal cell carcinoma	https://www.nice.org.uk/guidance/ta542
Capecitabine	Colorectal cancer	http://guidance.nice.org.uk/TA61
Capecitabine	Colon cancer (adjuvant)	http://guidance.nice.org.uk/TA100
Capecitabine	Gastric cancer (advanced)	http://guidance.nice.org.uk/TA191
Carmustine	Glioma (newly diagnosed and high-grade)	http://guidance.nice.org.uk/TA121
Cetuximab and panitumumab	Previously untreated metastatic colorectal cancer	https://www.nice.org.uk/guidance/ta439
Cetuximab	Head and neck cancer	http://guidance.nice.org.uk/TA145
Cetuximab	Colorectal cancer (first-line treatment)	http://guidance.nice.org.uk/TA176
Cetuximab	Recurrent or metastatic squamous cell cancer of the head and neck	https://www.nice.org.uk/guidance/ta473
Cetuximab	Previously untreated metastatic colorectal cancer	https://www.nice.org.uk/guidance/ta439
Cladribine	Relapsing–remitting multiple sclerosis (This may be possible to prescribe under shared care with an NHS England approved Tertiary Centre for MS)	https://www.nice.org.uk/guidance/ta493
Cobimetinib	In combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma	https://www.nice.org.uk/guidance/ta414
Collagenase clostridium histolyticum	Dupuytren's contracture	https://www.nice.org.uk/guidance/ta459
Crizotinib	Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	https://www.nice.org.uk/guidance/ta406
Crizotinib	Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	https://www.nice.org.uk/guidance/ta422
Dabrafenib with trametinib	Adjuvant treatment of resected BRAF V600 mutation-positive melanoma	https://www.nice.org.uk/guidance/ta544
Dabrafenib	Unresectable or metastatic BRAF V600 mutation positive melanoma	https://www.nice.org.uk/guidance/ta321
Daclatasvir	Chronic hepatitis C	http://www.nice.org.uk/guidance/ta364
Daclizumab	Renal transplantation – immunosuppressive regimens (adults)	http://guidance.nice.org.uk/TA85
Daclizumab	Renal transplantation – immunosuppressive regimens for children and adolescents	http://guidance.nice.org.uk/TA99
Degarelix	Advanced hormone-dependent prostate cancer	https://www.nice.org.uk/guidance/ta404
Dinutuximab beta	Neuroblastoma	https://www.nice.org.uk/guidance/ta538
Docetaxel	Prostate cancer (hormone-refractory)	http://guidance.nice.org.uk/TA101
Docetaxel	Breast cancer (early)	http://guidance.nice.org.uk/TA109
Doxorubicin	Ovarian cancer (advanced) – review	https://www.nice.org.uk/guidance/ta389

Eculizumab	Atypical haemolytic uraemic syndrome	https://www.nice.org.uk/guidance/hst1
Elbasvir–grazoprevir	Chronic hepatitis C	https://www.nice.org.uk/guidance/ta413
Eliglustat	Type 1 Gaucher disease	https://www.nice.org.uk/guidance/hst5
Encorafenib with binimetinib	Unresectable or metastatic BRAF V600 mutation-positive melanoma	https://www.nice.org.uk/guidance/ta562
Entecavir	Hepatitis B	http://guidance.nice.org.uk/TA153
Enzalutamide	Metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen	https://www.nice.org.uk/Guidance/TA316
Enzalutamide	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	https://www.nice.org.uk/guidance/ta377
Eribulin	Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	https://www.nice.org.uk/guidance/ta423
Erlotinib	Lung cancer (non-small cell)	http://guidance.nice.org.uk/TA162
Erlotinib	Lung cancer (non-small cell, EGFR-TK mutation positive, first-line treatment)	http://guidance.nice.org.uk/TA258
Erlotinib	Non-small-cell lung cancer that has progressed after prior chemotherapy	http://www.nice.org.uk/guidance/ta374
Etelcalcetide	Secondary hyperparathyroidism	https://www.nice.org.uk/guidance/ta448
Everolimus	Advanced renal cell carcinoma after previous treatment	https://www.nice.org.uk/guidance/ta432
Everolimus	Advanced breast cancer after endocrine therapy	https://www.nice.org.uk/guidance/ta421
Everolimus	Unresectable or metastatic neuroendocrine tumours in people with progressive disease	https://www.nice.org.uk/guidance/ta449
Evolocumab	Primary hypercholesterolaemia or mixed dyslipidaemia. (Restricted to named specialist centres only)	https://www.nice.org.uk/guidance/ta394
Gefitinib	Lung cancer (non-small cell, first-line treatment)	http://guidance.nice.org.uk/TA192
Gefitinib	Non-small-cell lung cancer that has progressed after prior chemotherapy	http://www.nice.org.uk/guidance/ta374
Gemcitabine	Pancreatic cancer	http://guidance.nice.org.uk/TA25
Gemcitabine	Breast cancer	http://guidance.nice.org.uk/TA116
Gemcitabine	Ovarian cancer (advanced) – review	https://www.nice.org.uk/guidance/ta389
Glecaprevir–pibrentasvir	Chronic hepatitis C	https://www.nice.org.uk/guidance/ta499
Holoclar	Limbal stem cell deficiency after eye burns	https://www.nice.org.uk/guidance/ta467
Imatinib	Gastrointestinal stromal tumours	http://guidance.nice.org.uk/TA86
Imatinib	Gastrointestinal stromal tumours (unresectable/metastatic)	http://guidance.nice.org.uk/TA209
Imatinib	Adjuvant treatment of gastrointestinal stromal tumours	https://www.nice.org.uk/guidance/ta326
Immunosuppressive therapy	Kidney transplant in adults	https://www.nice.org.uk/guidance/ta481
Immunosuppressive therapy	kidney transplant in children and young people	https://www.nice.org.uk/guidance/ta482
Inotuzumab ozogamicin	Relapsed or refractory B-cell acute lymphoblastic leukaemia	https://www.nice.org.uk/guidance/ta541
Intrabeam radiotherapy system	Adjuvant treatment of early breast cancer	https://www.nice.org.uk/guidance/ta501
Ipilimumab	Previously treated advanced (unresectable or	http://guidance.nice.org.uk/TA268

	metastatic) melanoma	
Ipilimumab	Previously untreated advanced (unresectable or metastatic) melanoma	https://www.nice.org.uk/Guidance/TA319
Lapatinib	Breast cancer (metastatic hormone receptor) with aromatase inhibitor	http://guidance.nice.org.uk/TA257
Ledipasvir–sofosbuvir	Chronic hepatitis C	http://www.nice.org.uk/guidance/ta363
Lenvatinib with everolimus	Previously treated advanced renal cell carcinoma	https://www.nice.org.uk/guidance/ta498
Lenvatinib and sorafenib	Differentiated thyroid cancer after radioactive iodine	https://www.nice.org.uk/guidance/ta535
Lenvatinib	Untreated advanced hepatocellular carcinoma	https://www.nice.org.uk/guidance/ta551
Liposomal cytarabine–daunorubicin	Untreated acute myeloid leukaemia Patients will be treated at RSCH as inpatient.	https://www.nice.org.uk/guidance/ta552
Lutetium (177Lu) oxodotreotide	Unresectable or metastatic neuroendocrine tumours	https://www.nice.org.uk/guidance/ta539
Mepolizumab	Severe refractory eosinophilic asthma. Please note: pending NHS England ‘small services’ review of ASPH Q4 2016/17 this may change.	https://www.nice.org.uk/guidance/ta431
Midostaurin	Untreated acute myeloid leukaemia	https://www.nice.org.uk/guidance/ta523
Mifamurtide	Osteosarcoma	http://guidance.nice.org.uk/TA235
Migalastat	Fabry disease	https://www.nice.org.uk/guidance/hst4
Nalmefene	Reducing alcohol consumption in people with alcohol dependence	https://www.nice.org.uk/guidance/ta325
Necitumumab	Untreated advanced or metastatic squamous non-small-cell lung cancer	https://www.nice.org.uk/guidance/ta411
Nintedanib	Locally advanced, metastatic or locally recurrent non-small-cell lung cancer	http://www.nice.org.uk/guidance/ta347
Niraparib	Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	https://www.nice.org.uk/guidance/ta528
Nivolumab	Advanced (unresectable or metastatic) melanoma	https://www.nice.org.uk/guidance/ta384
Nivolumab	Advanced (unresectable or metastatic) melanoma in adults, in combination with ipilimumab	https://www.nice.org.uk/guidance/ta400
Nivolumab	Previously treated advanced renal cell carcinoma	https://www.nice.org.uk/guidance/ta417
Nivolumab	Squamous cell carcinoma of the head and neck after platinum-based chemotherapy	https://www.nice.org.uk/guidance/ta490
Nivolumab	Completely resected melanoma with lymph node involvement or metastatic disease	https://www.nice.org.uk/guidance/ta558
Olaparib	Maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy	https://www.nice.org.uk/guidance/ta381
Olaratumab in combination with doxorubicin	Advanced soft tissue sarcoma	https://www.nice.org.uk/guidance/ta465
Ombitasvir–paritaprevir–	With or without dasabuvir for treating chronic hepatitis C	http://www.nice.org.uk/guidance/ta365

ritonavir		
Osimertinib	Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer	https://www.nice.org.uk/guidance/ta416
Oxaliplatin	Colon cancer (adjuvant)	http://guidance.nice.org.uk/TA100
Paclitaxel	Ovarian cancer – review	http://guidance.nice.org.uk/TA55
Paclitaxel	Ovarian cancer (advanced) – review	https://www.nice.org.uk/guidance/ta389
Paclitaxel	As albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer	https://www.nice.org.uk/guidance/ta476
Pazopanib	Renal cell carcinoma (first-line metastatic)	http://guidance.nice.org.uk/TA215
Pegaspargase	Acute lymphoblastic leukaemia	https://www.nice.org.uk/guidance/ta408
Pegylated interferons	Hepatitis C	http://guidance.nice.org.uk/TA75
Pegylated interferon alfa 2a	Hepatitis B (chronic)	http://guidance.nice.org.uk/TA96
Peginterferon alfa	Hepatitis C	http://guidance.nice.org.uk/TA106
Peginterferon alfa	Hepatitis C	http://guidance.nice.org.uk/TA200
Peginterferon alfa with Ribavirin	Hepatitis C	http://guidance.nice.org.uk/TA300
Pembrolizumab	Advanced Melanoma	http://www.nice.org.uk/guidance/ta357
Pembrolizumab	Advanced melanoma not previously treated with ipilimumab	http://www.nice.org.uk/guidance/ta366
Pembrolizumab	Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	https://www.nice.org.uk/guidance/ta519
Pembrolizumab	Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	https://www.nice.org.uk/guidance/ta522
Pembrolizumab	Resected melanoma with high risk of recurrence	https://www.nice.org.uk/guidance/ta553
Pemetrexed	Mesothelioma	http://guidance.nice.org.uk/135
Pertuzumab	neoadjuvant treatment of HER2-positive breast cancer	https://www.nice.org.uk/guidance/ta424
Pharmalgen	Venom anaphylaxis – immunotherapy Pharmalgen	http://guidance.nice.org.uk/TA246
Radium-223 dichloride	Hormone-relapsed prostate cancer with bone metastases	https://www.nice.org.uk/guidance/ta376
Radium-223 dichloride	Hormone-relapsed prostate cancer with bone metastases	https://www.nice.org.uk/guidance/ta412
Ramucirumab	Previously treated locally advanced or metastatic non-small-cell lung cancer	https://www.nice.org.uk/guidance/ta403
Regorafenib	Previously treated unresectable or metastatic gastrointestinal stromal tumours	https://www.nice.org.uk/guidance/ta488
Regorafenib	Previously treated advanced hepatocellular carcinoma	https://www.nice.org.uk/guidance/ta555
Reslizumab	Severe eosinophilic asthma <i>*Note: This is subject to change if ASPH is approved as a specialist centre for Respiratory/Asthma.*</i>	https://www.nice.org.uk/guidance/ta479
Ribavirin	Hepatitis C	http://guidance.nice.org.uk/TA75
Ribavirin	Hepatitis C	http://guidance.nice.org.uk/TA106
Ribavirin	Hepatitis C	http://guidance.nice.org.uk/TA200

Riluzole	Motor neurone disease	http://guidance.nice.org.uk/TA20
Simeprevir	In combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C	https://www.nice.org.uk/guidance/ta331
Sirolimus	Renal transplantation – immunosuppressive regimens (adults)	http://guidance.nice.org.uk/TA85
Sirolimus	Renal transplantation – immunosuppressive regimens for children and adolescents	http://guidance.nice.org.uk/TA99
Sofosbuvir	Chronic Hepatitis C	https://www.nice.org.uk/guidance/ta330
Sofosbuvir – velpatasvir	Chronic Hepatitis C	https://www.nice.org.uk/guidance/ta430
Sofosbuvir– velpatasvir– voxilaprevir	Chronic Hepatitis C	https://www.nice.org.uk/guidance/ta507
Sorafenib	Advanced hepatocellular carcinoma	https://www.nice.org.uk/guidance/ta474
Sunitinib	Renal cell carcinoma	http://guidance.nice.org.uk/TA169
Sunitinib	Gastrointestinal stromal tumours	http://guidance.nice.org.uk/TA179
Sunitinib	Unresectable or metastatic neuroendocrine tumours in people with progressive disease	https://www.nice.org.uk/guidance/ta449
Tacrolimus	Renal transplantation – immunosuppressive regimens (adults)	http://guidance.nice.org.uk/TA85
Tacrolimus	Renal transplantation – immunosuppressive regimens for children and adolescents	http://guidance.nice.org.uk/TA99
Talimogene laherparepvec	Unresectable metastatic melanoma	https://www.nice.org.uk/guidance/ta410
Tegafur uracil	Colorectal cancer	http://guidance.nice.org.uk/TA61
Telaprevir	Hepatitis C (genotype 1)	http://guidance.nice.org.uk/TA252
Temozolamide	Brain cancer	https://www.nice.org.uk/guidance/ta23
Temozolamide	Glioma (newly diagnosed and high-grade)	http://guidance.nice.org.uk/TA121
Tenofovir	Hepatitis B	http://guidance.nice.org.uk/TA173
Tisagenlecleucel	Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years	https://www.nice.org.uk/guidance/ta554
Tisagenlecleucel	Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies	https://www.nice.org.uk/guidance/ta567
Tivozanib	Advanced renal cell carcinoma	https://www.nice.org.uk/guidance/ta512
Tocilizumab	Giant cell arteritis (Tertiary Centres Only)	https://www.nice.org.uk/guidance/ta518
Topotecan	Ovarian cancer (advanced) – review	https://www.nice.org.uk/guidance/ta389
Topotecan	Cervical cancer (recurrent)	http://guidance.nice.org.uk/TA183
Topotecan	Lung cancer (small cell)	http://guidance.nice.org.uk/TA184
Trabectedin	Soft tissue sarcoma	http://guidance.nice.org.uk/TA185
Trabectedin	Ovarian cancer (advanced) – review	https://www.nice.org.uk/guidance/ta389
Trametinib	In combination with dabrafenib for treating unresectable or metastatic melanoma	https://www.nice.org.uk/guidance/ta396
Trifluridine	Previously treated metastatic colorectal cancer	https://www.nice.org.uk/guidance/ta405
Vemurafenib	Melanoma (BRAF V600 mutation positive, unresectable metastatic)	http://guidance.nice.org.uk/TA269
Vismodegib	Basal cell carcinoma	https://www.nice.org.uk/guidance/ta489

Vortioxetine	Major depressive episodes	http://www.nice.org.uk/guidance/ta367
---------------------	---------------------------	---